Status:
COMPLETED
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
Lead Sponsor:
Pfizer
Conditions:
HIV-1 Infection
Eligibility:
All Genders
Brief Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Local Product Document (LPD) (unlisted adverse drug reaction), 2) the incidence of adv...
Detailed Description
All the patients whom an investigator prescribes the first Rescriptor® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into ...
Eligibility Criteria
Inclusion
- Patients need to be administered Rescriptor® in order to be enrolled in the surveillance.
Exclusion
- Patients not administered Rescriptor®.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00823966
Start Date
December 1 2003
End Date
March 1 2009
Last Update
July 5 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.